Cellumed Co. Ltd (049180) - Total Assets
Based on the latest financial reports, Cellumed Co. Ltd (049180) holds total assets worth ₩71.62 Billion KRW (≈ $48.54 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Cellumed Co. Ltd (049180) net assets for net asset value and shareholders' equity analysis.
Cellumed Co. Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Cellumed Co. Ltd's total assets have evolved over time, based on quarterly financial data.
Cellumed Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Cellumed Co. Ltd's total assets of ₩71.62 Billion consist of 74.5% current assets and 25.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 13.7% |
| Accounts Receivable | ₩23.21 Billion | 33.0% |
| Inventory | ₩7.06 Billion | 10.1% |
| Property, Plant & Equipment | ₩4.79 Billion | 6.8% |
| Intangible Assets | ₩31.79 Million | 0.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Cellumed Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cellumed Co. Ltd (049180) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cellumed Co. Ltd's current assets represent 74.5% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2024, up from 10.1% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 132.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 33.0% of total assets.
Cellumed Co. Ltd Competitors by Total Assets
Key competitors of Cellumed Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
iRay Technology Co Ltd
SHG:688301
|
China | CN¥11.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
China | CN¥993.46 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Cellumed Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.05 | 1.38 | 1.86 |
| Quick Ratio | 0.89 | 1.19 | 1.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩2.51 Billion | ₩14.77 Billion | ₩22.30 Billion |
Cellumed Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Cellumed Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.87 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | ₩70.22 Billion |
| Market Capitalization | $37.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cellumed Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Cellumed Co. Ltd's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cellumed Co. Ltd (2008–2024)
The table below shows the annual total assets of Cellumed Co. Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩70.22 Billion ≈ $47.59 Million |
+5.65% |
| 2023-12-31 | ₩66.47 Billion ≈ $45.05 Million |
-28.72% |
| 2022-12-31 | ₩93.26 Billion ≈ $63.20 Million |
-3.23% |
| 2021-12-31 | ₩96.37 Billion ≈ $65.31 Million |
+36.11% |
| 2020-12-31 | ₩70.80 Billion ≈ $47.98 Million |
+8.96% |
| 2019-12-31 | ₩64.98 Billion ≈ $44.04 Million |
+31.06% |
| 2018-12-31 | ₩49.58 Billion ≈ $33.60 Million |
-23.71% |
| 2017-12-31 | ₩64.98 Billion ≈ $44.04 Million |
-6.89% |
| 2016-12-31 | ₩69.79 Billion ≈ $47.30 Million |
-14.89% |
| 2015-12-31 | ₩82.00 Billion ≈ $55.57 Million |
+16.47% |
| 2014-12-31 | ₩70.40 Billion ≈ $47.71 Million |
-9.48% |
| 2013-12-31 | ₩77.78 Billion ≈ $52.71 Million |
-5.82% |
| 2012-12-31 | ₩82.59 Billion ≈ $55.97 Million |
+4.21% |
| 2011-12-31 | ₩79.25 Billion ≈ $53.70 Million |
+27.16% |
| 2008-12-31 | ₩62.32 Billion ≈ $42.23 Million |
-- |
About Cellumed Co. Ltd
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more